CL-316243
guinea pig
The Dose Guy’s verdictSep 1, 20263 sources
CL-316243 is a spectacular fat-loss compound in rats and a non-event in primates. The beta-3 receptor it was built to hit works differently in human tissue than in rodent tissue, and when researchers tested it on isolated human and primate fat cells, nothing happened. No lipolysis. The rodent papers are real. They just do not apply to you.
What it is
A selective beta-3 adrenergic receptor agonist, built as a research tool for studying brown-fat activation and white-fat browning in rodents. In mice and rats, CL-316243 does exactly what you want a fat-loss drug to do: it cranks up thermogenesis, converts white fat into metabolically active tissue, improves insulin sensitivity, and drops body weight without cutting food intake. The problem is translational. Human beta-3 receptors have different pharmacology than rodent ones, and CL-316243 does not cross that gap. Primate adipose tissue barely expresses the receptor, and what expression exists does not respond to CL-316243.
If you have seen CL-316243 sold as a research chemical, that is a vendor bet on a rodent paper, not a real product. The one beta-3 agonist that actually activates brown fat in humans is mirabegron, an approved bladder drug, and even its metabolic effect is small.
What the research shows
The rodent evidence is extensive. The human evidence is one ex vivo study and a primate study, both showing CL-316243 does not work in higher species.
Realistic protocols
There is no human protocol to write. CL-316243 does not activate human beta-3 receptors at the concentrations that work in rodents, and no one has dosed it in a person. If you have bought it, you have bought a molecule designed for a species you are not. I would return it and put the money toward retatrutide or tirzepatide.
Side effects
No human has taken CL-316243 in any documented setting, so side-effect data does not exist:
Where to buy
No live listings from tracked vendors right now.
